½ÃÀ庸°í¼­
»óǰÄÚµå
1363185

ºÏ¹ÌÀÇ À¯¹æ Àç°Ç ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Á¦Ç°º°, Çü»óº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2023-2030³â)

North America Breast Reconstruction Market Size, Share & Trends Analysis Report By Product (Implant, Tissue Expander, Acellular Dermal Matrix), By Shape (Round Shape, Anatomical Shape), By End-use, By Region, And Segment Forecasts, 2023 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 90 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ºÏ¹ÌÀÇ À¯¹æ Àç°Ç ½ÃÀå ¼ºÀå ¹× µ¿Çâ :

ºÏ¹ÌÀÇ À¯¹æ Àç°Ç(Breast Reconstruction) ½ÃÀå ±Ô¸ð´Â 2023³âºÎÅÍ 2030³â±îÁö CAGR 6.8%·Î ¼ºÀåÇÏ¿© 2030³â±îÁö 3¾ï 6,620¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ´Â ÀÌ Áö¿ª ³» À¯¹æ¾Ï ȯÀÚ ¼ö°¡ Áõ°¡Çϱ⠶§¹®ÀÏ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ij³ª´Ù ¾Ï Çùȸ 2019¿¡ µû¸£¸é ¿©¼º 8¸í Áß 1¸íÀÌ À¯¹æ¾Ï Áø´ÜÀ»¹ÞÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ À¯»çÇÑ Ãâó¿¡ µû¸£¸é À¯¹æ¾ÏÀº ij³ª´Ù¿¡¼­ µÎ ¹øÂ°·Î ¸¹ÀÌ ¹ß»ýÇÏ´Â ¾ÏÀÔ´Ï´Ù. µû¶ó¼­ ij³ª´ÙÀÇ À¯¹æ¾Ï ȯÀÚ ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó ºÏ¹Ì À¯¹æ Àç°Ç ½ÃÀåÀÌ È°¼ºÈ­ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ ÀÌ Áö¿ª¿¡¼­´Â À¯¹æ Àç°Ç ¼ö¼úÀÇ ¼öµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¼ºÇü ¿Ü°ú ±â·Ï º¸°ü¼Ò¿¡ µû¸£¸é À¯¹æ ÀýÁ¦¼ú ÈÄ À¯¹æ Àç°Ç ¼ö¼úÀº 2015³â 19.4%¿¡¼­ 2018³â 53.4%·Î Áõ°¡Çß½À´Ï´Ù. ¸¶Âù°¡Áö·Î ij³ª´Ù ¾Ï Çùȸ¿¡ µû¸£¸é ij³ª´Ù ¿©¼º 5¸í Áß 1¸íÀº À¯¹æ ÀýÁ¦¼ú ÈÄ À¯¹æ Àç°Ç¼úÀ» ¹Þ½À´Ï´Ù. µû¶ó¼­ À¯¹æ Àç°Ç ¼ö¼úÀÇ Áõ°¡´Â ºÏ¹Ì À¯¹æ Àç°Ç ½ÃÀåÀ» ÁÖµµ ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ, ´Ù¾çÇÑ ÀÎ½Ä °³¼± Ä·ÆäÀÎÀÌ ½ÃÀ۵Ǹ鼭 ¿©¼ºµéÀÇ ÀνÄÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î À¯¹æ Àç°Ç ÀÎ½Ä Ä·ÆäÀÎÀº À¯¹æ¾Ï Áø´Ü ÈÄ À¯¹æ Àç°Ç¼ú¿¡ ´ëÇÑ ¿Ã¹Ù¸¥ °áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ¿©¼ºµéÀ» ±³À°Çϰí, Âü¿©¸¦ À¯µµÇϰí, ±ÇÇÑÀ» ºÎ¿©ÇÕ´Ï´Ù.

ºÏ¹Ì À¯¹æ Àç°Ç ½ÃÀåÀº COVID-19·Î ÀÎÇØ Ç϶ô¼¼¸¦ º¸¿´½À´Ï´Ù. ±×·¯³ª ÆÒµ¥¹Í ÀÌÈÄ¿¡´Â ½ÃÀåÀÌ Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Äڷγª19 ±â°£ µ¿¾È ¿¬±âµÇ¾ú´ø À¯¹æ È®´ë¼ú°ú °°Àº ¼±ÅÃÀû ¼ö¼úÀÌ Äڷγª19 ÀÌÈÄ ±â°£¿¡ ÁøÇàµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ¸¹Àº ±â¾÷µéÀÌ ½ÃÀåÀ» ¼±Á¡Çϱâ À§ÇØ Áö¿ª È®Àå, Á¦Ç° Ãâ½Ã, ÆÄÆ®³Ê½Ê µî ´Ù¾çÇÑ Àü·«À» ÆîÄ¡°í ÀÖ½À´Ï´Ù.

¿¹¸¦ µé¾î, 2021³â 4¿ù, Sientra, Inc.¿Í Butterfly Network´Â À¯¹æ º¸Çü¹° ȯÀÚÀÇ Áø´Ü °¨½Ã¸¦ °³¼±Çϱâ À§ÇÑ Àü·«Àû ÆÄÆ®³Ê½ÊÀ» ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ´Â Ç÷¡Æ¼³Ñ20 º¸Áõ ÇÁ·Î±×·¥À¸·Î µÞ¹ÞħµÇ´Â ȸ»çÀÇ ¾ÈÀü¼º ÇÁ·ÎÇÊÀ» °­È­ÇÏ´Â µ¥ µµ¿òÀÌ µÉ °ÍÀ¸·Î ¿¹»óµÇ¾ú½À´Ï´Ù. µû¶ó¼­ ÀÌ·¯ÇÑ »ç·Ê´Â COVID-19 ÀÌÈÄ ºÏ¹Ì À¯¹æ Àç°Ç ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÏ¹ÌÀÇ À¯¹æ Àç°Ç ½ÃÀå º¸°í¼­ÀÇ ÇÏÀ̶óÀÌÆ®

  • Á¦Ç°º°·Î ÀÓÇöõÆ® ºÎ¹®Àº 2022³â 63.5%ÀÇ ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ±×·¯³ª Á¶Á÷ È®Àå±â ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È CAGR 6.9%ÀÇ °¡Àå ºü¸¥ ¼ºÀå·ü·Î ¹ßÀüÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ´Â Á¶Á÷ È®Àå±â ºÎ¹® ³»¿¡¼­ Á¦Ç°ÀÇ Áøº¸·Î ÀÎÇÑ °ÍÀÔ´Ï´Ù.
  • Çü»óº°·Î ¿øÇü ºÎ¹®Àº 2022³â 55.3%ÀÇ ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ±×·¯³ª ÇØºÎÇÐÀû ÇüÅ´ ¿¹Ãø ±â°£ µ¿¾È CAGR 6.9%ÀÇ °¡Àå ºü¸¥ ¼ºÀå·üÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
  • ÃÖÁ¾ ¿ëµµ¿¡ µû¸£¸é º´¿ø ºÎ¹®Àº 2022³â µ¿¾È 55.3%ÀÇ Á¡À¯À²·Î ½ÃÀåÀ» µ¶Á¡ÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±×·¯³ª ¹Ì¿ë Ŭ¸®´Ð ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È CAGR 7.0%·Î °¡Àå ³ôÀº ¼ºÀå·üÀÌ ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. À̰ÍÀº ºÏ¹Ì¿¡¼­ ¹Ì¿ë»çÀÇ ¼ö°¡ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù.
  • Áö¿ª¿¡ µû¸£¸é ¹Ì±¹Àº 2022³â 74.4%ÀÇ ÃÖ´ë ÆÇ¸Å Á¡À¯À²·Î ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù. ÀÌ´Â ÀÌ ³ª¶óÀÇ À¯¹æ¾Ï ¹× À¯¹æ Àç°Ç ¼ö¼ú °Ç¼ö Áõ°¡ ¶§¹®ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý ¹× ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ºÏ¹ÌÀÇ À¯¹æ Àç°Ç ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • »óÀ§ ½ÃÀå Àü¸Á
    • °ü·Ã/ºÎ¼öÀûÀÎ ½ÃÀå Àü¸Á
  • º¸±Þ ¹× ¼ºÀå Àü¸Á ¸ÅÇÎ
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø ¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦ ¿äÀÎ ºÐ¼®
  • ºÏ¹ÌÀÇ À¯¹æ Àç°Ç ½ÃÀå ºÐ¼® µµ±¸
    • »ê¾÷ ºÐ¼®-Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®

Á¦4Àå ºÏ¹Ì À¯¹æ Àç°Ç ½ÃÀå : Á¦Ç°º° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÏ¹ÌÀÇ À¯¹æ Àç°Ç ½ÃÀå : Áß¿ä Æ÷ÀÎÆ®
  • ºÏ¹ÌÀÇ À¯¹æ Àç°Ç ½ÃÀå : Á¦Ç° µ¿Çâ ¹× ½ÃÀå Á¡À¯À² ºÐ¼®(2022³â, 2030³â)
  • ÀÓÇöõÆ®
  • Á¶Á÷ È®Àå±â
  • ¹«¼¼Æ÷ ÁøÇÇ ¸ÅÆ®¸¯½º

Á¦5Àå ºÏ¹ÌÀÇ À¯¹æ Àç°Ç ½ÃÀå : Çü»óº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÏ¹ÌÀÇ À¯¹æ Àç°Ç ½ÃÀå : Áß¿ä Æ÷ÀÎÆ®
  • ºÏ¹ÌÀÇ À¯¹æ Àç°Ç ½ÃÀå : Çü»óÀÇ ¿òÁ÷ÀÓ°ú ½ÃÀå Á¡À¯À² ºÐ¼®(2022³â, 2030³â)
  • ¿øÇü
  • ÇØºÎÇÐÀû Çü»ó

Á¦6Àå ºÏ¹ÌÀÇ À¯¹æ Àç°Ç ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÏ¹ÌÀÇ À¯¹æ Àç°Ç ½ÃÀå : Áß¿ä Æ÷ÀÎÆ®
  • ºÏ¹ÌÀÇ À¯¹æ Àç°Ç ½ÃÀå : ÃÖÁ¾ ¿ëµµº° µ¿Çâ ¹× ½ÃÀå Á¡À¯À² ºÐ¼®(2022³â, 2030³â)
  • º´¿ø
  • ¹Ì¿ë Ŭ¸®´Ð
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)

Á¦7Àå ºÏ¹ÌÀÇ À¯¹æ Àç°Ç ½ÃÀå : Áö¿ªº° ÃßÁ¤¡¤µ¿Ç⠺м®

  • Áö¿ªº° Àü¸Á
  • Áö¿ªº° ºÏ¹Ì À¯¹æ Àç°Ç ½ÃÀå : Áß¿ä Æ÷ÀÎÆ®
  • ºÏ¹Ì
    • ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø(2018-2030³â)
    • ¹Ì±¹
    • ij³ª´Ù

Á¦8Àå °æÀï ±¸µµ

  • ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷¿¡ ÀÇÇÑ ÃÖ±Ù µ¿Çâ ¹× ¿µÇ⠺м®
  • ½ÃÀå ÁøÃâ±â¾÷ ºÐ·ù
    • Mentor Worldwide LLC
    • AbbVie Inc.
    • Integra LifeSciences
    • Sientra, Inc.
    • Stryker
    • Establishment Labs
    • RTI Surgical
    • MTF Biologics
    • Surgical Innovation Associates
    • TELA Bio, Inc.
LYJ 23.11.01

North America Breast Reconstruction Market Growth & Trends:

The North America breast reconstruction market size is expected to reach USD 366.2 million by 2030, registering a CAGR of 6.8% from 2023 to 2030, according to a new report by Grand View Research, Inc..This can be credited to the increase in number of breast cancer patients within this region. For instance, as per the Canadian Cancer Society 2019, one in eight females is expected to be diagnosed with breast cancer. Moreover, as per a similar source, breast cancer is the second most occurring cancer in Canada. Thus, the increasing number of breast cancer patients in Canada is predicted to boost the North America Breast Reconstruction market.

Moreover, the number of breast reconstruction surgery is also increasing in this region. For instance, as per the Archives of Plastic Surgery, post-mastectomy breast reconstruction surgery has increased from 19.4% in 2015 to 53.4% in 2018. Similarly, as per the Canadian Cancer Society, one in every five women in Canada goes under breast reconstruction post-mastectomy. Thus, a rise in the number of breast reconstruction surgery is anticipated to drive the North America breast reconstruction market.

Furthermore, the initiation of various awareness campaigns is leading to rising awareness among women. For instance, the Breast Reconstruction Awareness Campaign educates, engages & empowers females to take the right decision regarding breast reconstruction, post breast cancer diagnosis.

The North America breast reconstruction market witnessed a dip due to COVID-19. However, post-pandemic, the market is projected to have a significant growth rate. Elective surgeries such as breast augmentation, which were postponed during COVID-19, are expected to be held in the post-COVID-19 period. Moreover, to capture the market, many companies are entering into various strategies such as geographic expansion, product launches, and partnerships.

For instance, in April 2021, Sientra, Inc. and the Butterfly Network announced a strategic partnership to improve diagnostic surveillance of breast implant patients. This was expected to help the company to strengthen its safety profile, which was backed by the Platinum20 warranty program. Therefore, such instances are expected to drive the North America breast reconstruction market in the post-COVID-19 period.

North America Breast Reconstruction Market Report Highlights:

  • In terms of product, the implants segment held the largest market share of 63.5% in 2022 in the market. However, the tissue expander segment is expected to develop with the fastest growth rate of 6.9% CAGR, during the forecast period. This can be credited to the advancement in the products within the tissue expander segment
  • Based on shape, the round shape segment held the largest share of 55.3% in 2022 in the market. However, the anatomical shape is anticipated to witness the fastest growth rate of CAGR of 6.9% during the forecast period
  • Based on end-use, the hospital segment was expected to dominate the market with a 55.3% share during 2022. However, the cosmetology clinics segment is projected to witness the highest growth rate of 7.0% CAGR during the forecast period. This can be credited to the rising number of cosmetologists in the North America region.
  • Based on the region, the U.S. dominated the market with the largest revenue share of 74.4% in 2022. This can be credited to the increase in number of breast cancer & breast reconstruction procedures within this nation

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. Shape
    • 1.1.3. End Use
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Shape outlook
    • 2.2.3. End use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. North America Breast Reconstruction Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. North America Breast Reconstruction Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's Five Forces
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. North America Breast Reconstruction Market: Product Estimates & Trend Analysis

  • 4.1. North America Breast Reconstruction Market: Key Takeaways
  • 4.2. North America Breast Reconstruction Market: Product Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Implants
    • 4.3.1. Implants market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.2. Silicone breast implants
      • 4.3.2.1. Silicone breast implants estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.3.3. Saline breast implants
      • 4.3.3.1. Saline breast implants estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Tissue Expander
    • 4.4.1. Tissue expander market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.2. Saline expander
      • 4.4.2.1. Saline expander estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.3. Air tissue expander
      • 4.4.3.1. Air tissue expander estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Acellular Dermal Matrix
    • 4.5.1. Acellular dermal matrix market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. North America Breast Reconstruction Market: Shape Estimates & Trend Analysis

  • 5.1. North America Breast Reconstruction Market: Key Takeaways
  • 5.2. North America Breast Reconstruction Market: Shape Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Round Shape
    • 5.3.1. Round shape market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Anatomical Shape
    • 5.4.1. Anatomical shape market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. North America Breast Reconstruction Market: End Use Estimates & Trend Analysis

  • 6.1. North America Breast Reconstruction Market: Key Takeaways
  • 6.2. North America Breast Reconstruction Market: End-use Movement & Market Share Analysis, 2022 & 2030
  • 6.3. Hospitals
    • 6.3.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4. Cosmetology Clinics
    • 6.4.1. Cosmetology clinics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.5. Ambulatory Surgical Centers
    • 6.5.1. Ambulatory surgical centers market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. North America Breast Reconstruction Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Outlook
  • 7.2. North America Breast Reconstruction Market by Region: Key Takeaways
  • 7.3. North America
    • 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Market Participant Categorization
    • 8.2.1. Mentor Worldwide LLC
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. AbbVie Inc.
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. Integra LifeSciences
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Sientra, Inc.
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Stryker
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. Establishment Labs
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. RTI Surgical
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. MTF Biologics
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Surgical Innovation Associates
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. TELA Bio, Inc.
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product benchmarking
      • 8.2.10.4. Strategic initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦